Nishadil
Signup Signin
Delhi | 25°C (windy)
The Great Divide: Weighing the High-Wire Act of Virios Against Lite Strategy's Steady Hand

The Great Divide: Weighing the High-Wire Act of Virios Against Lite Strategy's Steady Hand
The Siren Song of Scale: Why Big Pharma's Mega-Mergers So Often Fall Flat

The Siren Song of Scale: Why Big Pharma's Mega-Mergers So Often Fall Flat
Dragon's Roar in the Lab: How China's Biotech Ambitions Are Quietly Reshaping Global Pharma

Dragon's Roar in the Lab: How China's Biotech Ambitions Are Quietly Reshaping Global Pharma
The Curious Case of ORIC Pharma: Why Wall Street Just Tipped Its Hand on a Potential Upside

The Curious Case of ORIC Pharma: Why Wall Street Just Tipped Its Hand on a Potential Upside
The High Stakes Game: Dissecting Phathom Pharmaceuticals and Aravive's Biotech Fortunes

The High Stakes Game: Dissecting Phathom Pharmaceuticals and Aravive's Biotech Fortunes
Biotech Buzz: Leerink Partners Bets Big on Monopar's Future

Biotech Buzz: Leerink Partners Bets Big on Monopar's Future
Unpacking the Numbers: A Quiet Investment in Biotech and What it Means

Unpacking the Numbers: A Quiet Investment in Biotech and What it Means
The Biotech Divide: Why Big Players and Bold Newcomers Tell Different Investment Stories

The Biotech Divide: Why Big Players and Bold Newcomers Tell Different Investment Stories
A Second Look: Wall Street's Shifting Stance on Coherus BioSciences

A Second Look: Wall Street's Shifting Stance on Coherus BioSciences
The Biotech Crossroads: Where Vor Biopharma and Liminatus Pharma Stand in the Race for Innovation

The Biotech Crossroads: Where Vor Biopharma and Liminatus Pharma Stand in the Race for Innovation
The Unraveling of a Biotech Dream: When Investor Optimism Meets Harsh Reality

The Unraveling of a Biotech Dream: When Investor Optimism Meets Harsh Reality
The Biotech Battleground: What's Really Happening with aTyr Pharma Investors?

The Biotech Battleground: What's Really Happening with aTyr Pharma Investors?
When Giants Shift: Mitsubishi UFJ's Calculated Bet on Biotech's Next Horizon

When Giants Shift: Mitsubishi UFJ's Calculated Bet on Biotech's Next Horizon
The Whisper of an Exit: What Jack Kaye's uniQure Stock Sale Could Tell Us

The Whisper of an Exit: What Jack Kaye's uniQure Stock Sale Could Tell Us
Nektar Therapeutics: A Whisper of Change on Wall Street?

Nektar Therapeutics: A Whisper of Change on Wall Street?
Cellectis Charts Its Course: A Biotech Journey Through Research, Finances, and Hope

Cellectis Charts Its Course: A Biotech Journey Through Research, Finances, and Hope
The Biotech Beat: Why Wall Street's Whispers Are Turning to Crinetics

The Biotech Beat: Why Wall Street's Whispers Are Turning to Crinetics
The Shifting Sands of Scalp Science: Biotech's Bold Bet on Regrowing What We've Lost

The Shifting Sands of Scalp Science: Biotech's Bold Bet on Regrowing What We've Lost
Unpacking the Pulse: Janus Henderson's Life Sciences Playbook for Q3 2025

Unpacking the Pulse: Janus Henderson's Life Sciences Playbook for Q3 2025
The Shifting Tempo: Jazz Pharma's Q3 Crescendo Meets a Measured 2025 Outlook

The Shifting Tempo: Jazz Pharma's Q3 Crescendo Meets a Measured 2025 Outlook
Hope on the Horizon: Vera Therapeutics Charts a Course Through Critical Clinical Milestones

Hope on the Horizon: Vera Therapeutics Charts a Course Through Critical Clinical Milestones
The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown
The Biotech Crucible: Weighing the Risks and Rewards of Morphosys and Calithera Biosciences

The Biotech Crucible: Weighing the Risks and Rewards of Morphosys and Calithera Biosciences
Nautilus Bio Gets a Nuanced Nod: What Does 'Hold' Really Mean?

Nautilus Bio Gets a Nuanced Nod: What Does 'Hold' Really Mean?
CAR-T's Tightrope Walk: Why Autolus Faces an Uphill Battle Despite a Breakthrough

CAR-T's Tightrope Walk: Why Autolus Faces an Uphill Battle Despite a Breakthrough
The Unseen Momentum: Aadi Bioscience's Remarkable Ascent and the Hope it Carries

The Unseen Momentum: Aadi Bioscience's Remarkable Ascent and the Hope it Carries
Taysha Gene Therapies Stock Takes a Dive: Unpacking the Impact of Their Latest Public Offering

Taysha Gene Therapies Stock Takes a Dive: Unpacking the Impact of Their Latest Public Offering
Unlocking India's Pharmaceutical Future: The Urgent Need for a Homegrown Drug Innovation Ecosystem

Unlocking India's Pharmaceutical Future: The Urgent Need for a Homegrown Drug Innovation Ecosystem
The Biotech Imperative: Why India Must Lead the Next Scientific Revolution

The Biotech Imperative: Why India Must Lead the Next Scientific Revolution
Rezdiffra's Global Ascendancy: Madrigal Pharmaceuticals Reshaping NASH Treatment

Rezdiffra's Global Ascendancy: Madrigal Pharmaceuticals Reshaping NASH Treatment
Eupraxia Pharmaceuticals Secures $70 Million Through Public Offering to Accelerate Osteoarthritis Treatment Development

Eupraxia Pharmaceuticals Secures $70 Million Through Public Offering to Accelerate Osteoarthritis Treatment Development
Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave
The NAD+ Revolution: Why ChromaDex's Niagen is a Scientific Marvel Facing Financial Headwinds

The NAD+ Revolution: Why ChromaDex's Niagen is a Scientific Marvel Facing Financial Headwinds
Wave Life Sciences Plummets 19%, But Long-Term Investors See a Silver Lining

Wave Life Sciences Plummets 19%, But Long-Term Investors See a Silver Lining
Load more..